

Thank you for your interest in the actively enrolling studies currently being conducted by Mercy Research. Please use the column filter arrows to search for studies based on your interests. The far-right column includes a link to the NIH ClinicalTrials.gov page for each study, where you can find additional details. If you identify one or more studies you would like to learn more about or be considered for screening, please note the study name(s) and click the "Contact Us" button below to complete the form with the requested information including the study name(s) in the "Comments" section.

Contact Us

Focus Area	Category	Sub Category	Study Protocol #	Study Description	Mercy Location where Study is available	Study Information available at https://clinicaltrials.gov/
Non-Oncology	Cardiovascular	Peripheral Vascular Disease	SAMC CL-0005 POWER PAD 2	Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Peripheral Artery Disease	SAMC St. Louis South	NCT06457685
Non-Oncology	Critical Care	Pulmonary Embolism	SPRG PERT Consortium Registry	Pulmonary Embolism Response Team (PERT) Consortium Registry	Springfield	NA
Non-Oncology	Critical Care	Pulmonary Embolism	STLO PERT Consortium Registry	Pulmonary Embolism Response Team (PERT) Consortium Registry	St. Louis	NA
Non-Oncology	Interventional Radiology	Pulmonary Embolism	SAMC CLP 18135.A STRIKE-PE	STRIKE-PE: A Prospective, Multicenter Study of the Indigo™ Aspiration System Seeking to Evaluate the Long-Term Safety and Outcomes of Treating Pulmonary Embolism	SAMC St. Louis South	NCT04798261
Non-Oncology	Neurology/Neurosurgery-Acute (stroke)	Stroke - Hemorrhagic	SPRG STROKENET (ASPIRE)	Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery	Springfield	NCT03907046
Non-Oncology	Neurology_Other Nervous System	Stroke - Hemorrhagic	SAMC ASPIRE (StrokeNet)	Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery	SAMC St. Louis South	NCT03907046
Non-Oncology	Neurology_Other Nervous System	Stroke - Hemorrhagic	OKLC ASPIRE (StrokeNet)	Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery	Oklahoma City	NCT03907046
Non-Oncology	Neurology_Other Nervous System	Stroke - Ischemic	STLO STROKENET (ASPIRE)	Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery	St. Louis	NCT03907046
Non-Oncology	Plastic & Reconstructive Surgery		STLO RTI-CL-5000 ADMIRE	Acellular Dermal Matrix Investigation in Breast Reconstruction	St. Louis	NCT06456554
Non-Oncology	Plastic & Reconstructive Surgery		RSH OKLC RTI-CL-5000 ADMIRE	Acellular Dermal Matrix Investigation in Breast Reconstruction	Oklahoma City	NCT06456554
Non-Oncology	Pulmonology	Pulmonary Embolism	SPRG 23-001 PEERLESS II	PEERLESS II: RCT of FlowTrierer vs. Anticoagulation Alone in Pulmonary Embolism	Springfield	NCT06055920
Non-Oncology	Pulmonology	Pulmonary Hypertension	STLO PHAR Registry	Pulmonary Hypertension Association Registry (PHAR)	St. Louis	NCT04071327
Non-Oncology	Multi-Cancer Early Detection (MCED)		MW PM.RWD REACH GRAIL-MA-002	REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity	Mercy Clinical Research	NCT05673018
Oncology	Oncology, Pediatric/AYA	Acute Leukemia	APAL2020SC	The Pediatric Acute Leukemia (PaAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study	St. Louis	NCT04726241
Oncology	Oncology, Pediatric/AYA	Blood	ANHL2121	A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis	St. Louis	NCT05282069
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	AALL1621	Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	St. Louis	NCT02981628
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	AALL1732	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-Lly	St. Louis	NCT03959085
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	AALL1821	A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)	St. Louis	NCT04546399
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	AALL2131	A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)	St. Louis	NCT06124157
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	AALL2321	Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia	St. Louis	NCT06317662
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	AAML1831	A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations	St. Louis	NCT04293562
Oncology	Oncology, Pediatric/AYA	Blood, Leukemia	ACCL1931	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma	St. Louis	NCT05602194
Oncology	Oncology, Pediatric/AYA	Brain	ACNS1821	A Study of the Drug Salineox With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	St. Louis	NCT05099003

Oncology	Oncology, Pediatric/AYA	Brain	ACNS2021	A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT	St. Louis	NCT04684368
Oncology	Oncology, Pediatric/AYA	Brain	ANBL1531	Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)	St. Louis	NCT03126916
Oncology	Oncology, Pediatric/AYA	Brain	ANBL2131	Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma	St. Louis	NCT06172296
Oncology	Oncology, Pediatric/AYA	Data Collection	ALTE05N1	Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies	St. Louis	NCT00736749
Oncology	Oncology, Pediatric/AYA	Data Collection	APEC14B1	Project: Every Child for Younger Patients With Cancer	St. Louis	NCT02402244
Oncology	Oncology, Pediatric/AYA	GU, Renal Cell	AREN1921	A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWI	St. Louis	NCT04322318
Oncology	Oncology, Pediatric/AYA	GU, Renal Cell	AREN2231	A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWI)	St. Louis	NCT06401330
Oncology	Oncology, Pediatric/AYA	H&N, Melanoma	ARAR2221	A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)	St. Louis	NCT06064097
Oncology	Oncology, Pediatric/AYA	Hodgkin/non-Hodgkin Lymphoma	AHOD2131	A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab	St. Louis	NCT05675410
Oncology	Oncology, Pediatric/AYA	Hodgkin/non-Hodgkin Lymphoma	ALTE21C1	A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma	St. Louis	NCT05705531
Oncology	Oncology, Pediatric/AYA	n/a	APEC1621-MASTER	n/a	St. Louis	n/a
Oncology	Oncology, Pediatric/AYA	Osteosarcoma	AOST2031	Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma	St. Louis	NCT05235165
Oncology	Oncology, Pediatric/AYA	Osteosarcoma	AOST2032	A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma	St. Louis	NCT05691478
Oncology	Oncology, Pediatric/AYA	Soft Tissue Sarcoma	ARST2032	Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma	St. Louis	NCT05304585
Oncology	Biorepository_Tissue Bank	Bladder	RSH STLO Liquid Biopsy Biorepository	Liquid Biopsy for Detection of Minimal Residual Disease in High-Grade urothelial cancer	St. Louis	NA
Oncology	Biorepository_Tissue Bank	Gynecologic	STLO AOA-PRT-0001	Collection and Banking of Blood Samples for the Study of Female Gynecological Diseases	St. Louis	NA
Oncology	Biorepository_Tissue Bank	Oncology - Basket Solid Tumor	OKLC ELEPHAS-05	Live Tumor Collection for Development of an ex vivo Immunotherapy Prediction Platform	Oklahoma City	NA
Oncology	Biorepository_Tissue Bank	Oncology - Basket Solid Tumor	FTSM ELEPHAS-05	Live Tumor Collection for Development of an ex vivo Immunotherapy Prediction Platform	Fort Smith	NA
Oncology	Biorepository_Tissue Bank	Oncology - Basket Solid Tumor	SPRG ELEPHAS-05	Live Tumor Collection for Development of an ex vivo Immunotherapy Prediction Platform	Springfield	NA
Oncology	Biorepository_Tissue Bank	Oncology - Basket Solid Tumor	STLO ELEPHAS-05	Live Tumor Collection for Development of an ex vivo Immunotherapy Prediction Platform	St. Louis	NA
Oncology	Biorepository_Tissue Bank	Oncology - Basket Solid Tumor	SAMC ELEPHAS-05	Live Tumor Collection for Development of an ex vivo Immunotherapy Prediction Platform	SAMC St. Louis South	NA
Oncology	Immuno/Chemo-Infusion	Non-Small Cell Lung Cancer (NSCLC)	SAMC SMT112-3007 HARMONI-7	A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression	SAMC St. Louis South	NCT06767514
Oncology	Immunotherapy-Infusion	Melanoma	SAMC R3767-ONC-22122	A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma	SAMC St. Louis South	NCT06246916
Oncology	Immunotherapy-Infusion	Non-Small Cell Lung Cancer (NSCLC)	STLO MK2870-019	A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery	St. Louis	NCT06312137
Oncology	Immunotherapy-Infusion	Non-Small Cell Lung Cancer (NSCLC)	STLO MK2870-019	A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery	SAMC St. Louis South	NCT06312137
Oncology	Immunotherapy-Infusion	Non-Small Cell Lung Cancer (NSCLC)	SAMC ZL-1310-003 DLEVATE	A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer	SAMC St. Louis South	NCT07218146
Oncology	Immunotherapy-Viral	Gynecologic	STLO GOG-3076 OnPrime	A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)	St. Louis	NCT05281471

Oncology	Intratumoral Immunotherapy		STLO LEGION-100	A Phase 2a Multicenter Dose Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).	St. Louis	NCT06533644
Oncology	Minimal Residual Disease (MRD)	Non-Small Cell Lung Cancer (NSCLC)	STLO PM.RWD TP-CA-002 GEMINI-NSCLC	Tempus NSCLC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	St. Louis	NCT05236114
Oncology	Minimal Residual Disease (MRD)	Non-Small Cell Lung Cancer (NSCLC)	SPRG PM.RWD TP-CA-002 GEMINI-NSCLC	Tempus NSCLC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	Springfield	NCT05236114
Oncology	Minimal Residual Disease (MRD)	Non-Small Cell Lung Cancer (NSCLC)	FTSM PM.RWD TP-CA-002 GEMINI-NSCLC	Tempus NSCLC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	Fort Smith	NCT05236114
Oncology	Minimal Residual Disease (MRD)	Non-Small Cell Lung Cancer (NSCLC)	OKLC PM.RWD TP-CA-002 GEMINI-NSCLC	TEMPUS NSCLC SURVEILLANCE STUDY: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	Oklahoma City	NCT05236114
Oncology	Minimal Residual Disease (MRD)	Non-Small Cell Lung Cancer (NSCLC)	JOPL PM.RWD TP-CA-002 GEMINI-NSCLC	Tempus NSCLC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	Joplin	NCT05236114
Oncology	Minimal Residual Disease (MRD)	Non-Small Cell Lung Cancer (NSCLC)	SAMC PM.RWD TP-CA-002 GEMINI-NSCLC	Tempus NSCLC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays	SAMC St. Louis South	NCT05236114
Oncology	PARB Inhibitor-Oral	Breast	SPRG D9722C00001 EvoPAR-Breast01 Tempus Time Trial	A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+ / ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)	Springfield	NCT06380751
Oncology	Proton Beam Therapy	Genitourinary	STLO PCG GU010-18	Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy. Purpose is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable) has on prostate cancer that has already returned or the risk of prostate cancer returning.	St. Louis	NCT00969111
Oncology	Proton Beam Therapy	Genitourinary	STLO PCG REG001-09 Registry	Proton Collaborative Group Protocol REG001-08	St. Louis	NA
Oncology	Registry	Non-Small Cell Lung Cancer (NSCLC)	FTSM PrE1702	Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients	Fort Smith	NCT06538038
Oncology	Registry	Non-Small Cell Lung Cancer (NSCLC)	SAMC PrE1702	Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients	SAMC St. Louis South	NCT06538038
Oncology	Registry	Non-Small Cell Lung Cancer (NSCLC)	STLO PrE1702	Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients	St. Louis	NCT06538038
Oncology	Registry	Non-Small Cell Lung Cancer (NSCLC)	OKLC PrE1702	Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients	Oklahoma City	NCT06538038
Oncology	Registry	Non-Small Cell Lung Cancer (NSCLC)	JOPL PrE1702	Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients	Joplin	NCT06538038
Oncology	Registry	Non-Small Cell Lung Cancer (NSCLC)	SPRG PrE1702	Prospective Non-Interventional Study Comparing Standard of Care Osimertinib +/- Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patients	Springfield	NCT06538038
Oncology	Cancer Care Delivery Research (CCDR)	Colorectal Cancer Surveillance	SWOG S2417CD	A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07018869
Oncology	Cancer Care Delivery Research (CCDR)	Financial Impact/Solid Tumors	EAQ222CD	Effectiveness of Out-of-Pocket Cost Communication and Financial Navigation (CostCOM) in Cancer Patients	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06295367
Oncology	Cancer Care Delivery Research (CCDR)	Genetic services/AYA Community	Alliance A232301CD	AYA ACCESS Study: An enhanced eHealth and Chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07091617
Oncology	Cancer Care Delivery Research (CCDR)	Genetic services/AYA Community	Alliance A232402CD	AYA ACCESS Study: An enhanced eHealth and Chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07283939
Oncology	Cancer Care Delivery Research (CCDR)	Geriatric Assessment/Opt 1	WF-2501CD	Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07225920
Oncology	Cancer Care Delivery Research (CCDR)	GI, GU or GYN Cancer Surgery Practices	WF-2502CD	Surgical Thromboprophylaxis Practices in Oncology Patients within the NCCORP Network (STOP-VTE)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07215624
Oncology	Cancer Care Delivery Research (CCDR)	HRSN (health-related social needs)	WF-2303CD	Understanding and Enhancing Health-related Social Needs (HRSN) Screening Among Community Oncology Practices	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06412029
Oncology	Cancer Care Delivery Research (CCDR)	Lung, or H&N pt, RadOnc & Radiologist Team	WF-2402CD	Collaborative Oncology between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets (CORRECT)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07282444
Oncology	Cancer Care Delivery Research (CCDR)	Meds compliance-Breast	EAQ221CD	Improving Medication Adherence in Breast Cancer using a CONnected CUsomized Treatment Platform (CONCURxP)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06112613
Oncology	Cancer Care Delivery Research (CCDR)	symptom & distress mgmt	NRG-CC012CD	Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06279013
Oncology	Cancer Control, Breast focused	Cardiac toxicity in breast cancer	SWOG S1501	Arm 3 =ONLY active arm Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03418961

Oncology	Cancer Control, Breast focused	Cognitive Training	NRG-CC011	Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05896189
Oncology	Cancer Control, Breast focused	Depression & Breast Cancer	NRG-CC015	Req'd: Referral Provider/Facility & Depression Screening Form Harnessing E-Mindfulness Approaches for Living-After Breast Cancer – HEAL-ABC	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06748222
Oncology	Cancer Control, Breast focused	Overall Survival Breast Cancer	SWOG S1703	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDMM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03723928
Oncology	Cancer Control, GI focused	Chemo toxicity in older adults w/colorectal cancer	Wake Forest WF-1806	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03998202
Oncology	Cancer Control, GI focused	Colonoscopy	NRG-CC005	FORTE: A study to determine whether a colonoscopy should be done every 5 years or every 10 years in people with 1 or 2 small growths (polyps) removed from their colon	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05080673
Oncology	Cancer Control, GU focused	Prostate	URCC-22053	Req'd: Coordinator Training, DXA Machine Cert & DXA Tech Cert High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05838716
Oncology	Cancer Control, GYN focused	BRACA 1 Carriers	NRG-CC008	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04251052
Oncology	Cancer Control, GYN focused	Lymph node	NRG-CC010	CC010 Surgeon Credentialing A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05646316
Oncology	Cancer Control, Head & Neck focused	Oral Mucositis	Alliance A222301	Pre-Reg Require: Site DTL High-dose Prophylactic Gabapentin (HOPE) to Prevent Opioid use for Oral Mucositis Pain during Head and Neck Chemoradiotherapy: A Phase III Clinical trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06992427
Oncology	Cancer Control, Head & Neck focused	Oral Mucositis	NRG-CC013	Pre-Reg Require: Study Agent Shipment form, Radiation Credentialing & Site DTL A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06532279
Oncology	Cancer Control, Leukemia-Focused	Tyrosine Kinase Inhibitor for CML or CLL	URCC-24060	Req't: Protocol Training Impact of Targeted Therapy on Cancer-Related Cognitive Impairment	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Cancer Control, Lung focused	Brain Mets Sm Cell Lung	NRG-CC009	Pre-Reg: Neurocog, IMRT & SRS Cred & Hippo. Phy Cred Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04804644
Oncology	Cancer Control, Multiple Sites focused	Advanced Practice Mentorship	Wake Forest WF-2403	Req'd: Site Open To Enrollment (SOTE) letter Building Capacity within the NCCRP Network through an Education and Mentorship Intervention for Advanced Practice Providers (COACH-APP)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Cancer Control, Multiple Sites focused	Cancer Cachexia	URCC-22063	Req'd: Coordinator Training Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia (LOTUS)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06073431
Oncology	Cancer Control, Multiple Sites focused	Carboplatin predictors	NRG-GY022	***OPEN to MALE pt only*** Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03997370
Oncology	Cancer Control, Multiple Sites focused	Chemo-ICI Therapy-Solid Tumors	SWOG S2013	Cohort 2 (Chemo-ICI) OPEN Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04871542
Oncology	Cancer Control, Multiple Sites focused	Data Collection	NCI DCP-001	Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Cancer Control, Multiple Sites focused	Improv Data Collection	ECOG-ACRIN EAQ202	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05108298
Oncology	Cancer Control, Multiple Sites focused	Improve cancer related insomnia	URCC-19185	Study specific training Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04829539
Oncology	Cancer Control, Multiple Sites focused	Improving QOL for older survivors	URCC-19178	Optimizing Functional Outcomes of Older Cancer Survivors After Chemotherapy	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05006482
Oncology	Cancer Control, Multiple Sites focused	Ovarian Reserve protection	ALTE2131	AYA Trial-available to adults to 40 at all sites; under 18 at Mercy STL Peds clinic Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06513962
Oncology	Cancer Control, Multiple Sites focused	Smoking cessation-any cancer diag	Alliance A211901	Req'd: Site Mosio Username Request Form Reaching Rural Cancer Survivors Who Smoke using Text-Based Cessation Interventions	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05008848
Oncology	Cancer Control, Multiple Sites focused	Symptom Management	WF2304-A172401	Reqmts: CLASS Site Training, SOTE Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06418204
Oncology	Immunotherapy-Infusion	Endometrial	RSH SPRG GOG-3098 (D781DC00001) DESTINY-Endometrial01	DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01)	Springfield	NCT06989112
Oncology	Oncology, Blood	Blood, Leukemia	MYELO-MATCH	Req: CLASS MYELOMATCH Site Initiation Training & Site DTL MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Oncology, Blood	Blood, Leukemia	Alliance A041703	Req'd: Site DTL A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive, B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03739814
Oncology	Oncology, Blood	Blood, Leukemia	ECOG-ACRIN EA9181	Site Specific DTL req'd A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04530565

Oncology	Oncology, Blood	Blood, Leukemia	ECOG-ACRIN EA9213	A Phase II Trial of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Oncology, Blood	Blood, Leukemia	SWOG S1925	Site DTL Req'd Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04269902
Oncology	Oncology, Blood	Blood, Myeloma	ECOG-ACRIN EAA173	ePRO Training Req'd Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03937635
Oncology	Oncology, Blood	Blood, Myeloma	ECOG-ACRIN EAA181	Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04566328
Oncology	Oncology, Blood	Blood, Myeloma	SWOG S2209	A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05561387
Oncology	Oncology, Brain	Brain	Alliance A071401	Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT02523014
Oncology	Oncology, Brain	Brain	Alliance A072201	Req'd: Site DTL Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06325683
Oncology	Oncology, Brain	Brain	Alliance A072301	Req'd: Site DTL, IMRT, 3D & Proton (optional by site) credentialing Phase III trial of radiotherapy followed by adjuvant temozolomide in combination with the IDH inhibitor vorasidenib vs. placebo in IDH-mutated newly-diagnosed grade 3 astrocytomas	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07215910
Oncology	Oncology, Brain	Brain	CCTG CE.7	Site RT Credentialing & Neurocognitive Certification A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03550391
Oncology	Oncology, Brain	Brain	NRG-BN003	Site Credentialing Required Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03180268
Oncology	Oncology, Brain	Brain	NRG-BN013	Req'd: IRGT & SRS Credentialing Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06500455
Oncology	Oncology, Brain	Brain	NRG-BN014	Pre-Reg Reqs: IMRT & PROTONS Credentialing A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (RADIATE-LM)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06500481
Oncology	Oncology, Breast	Breast, Adjuvant	Alliance A012103	Site DTL Req'd OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05812807
Oncology	Oncology, Breast	Breast, Adjuvant	Alliance A012303	Site DTL Req'd ShortStop-HER2: Shortened duration of adjuvant therapy in patients with early-stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade.	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06876714
Oncology	Oncology, Breast	Breast, Adjuvant	NRG-BR007	IMRT Credentialing req'd A Phase III Clinical Trial Evaluating DE-escalation of Breast Radiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score less than or equal to 18 Breast Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04852887
Oncology	Oncology, Breast	Breast, Adjuvant	NRG-BR009	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score<= 25 (OFSET)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05879926
Oncology	Oncology, Breast	Breast, Neoadjuvant	SWOG S2206	Site DTL Req'd Phase III Trial of Neoadjuvant Duvulimab (NSC 779709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06058377
Oncology	Oncology, Breast	Breast, Neoadjuvant	SWOG S2212	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05929768
Oncology	Oncology, Breast	Breast-focused	NRG-CC011	Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05896189
Oncology	Oncology, Breast	Breast-focused	NRG-CC015	Req'd: Referral Provider/Facility & Depression Screening Form Harnessing E-Mindfulness Approaches for Living-After Breast Cancer – HEAL-ABC	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06748222
Oncology	Oncology, Breast	Breast-focused	SWOG S1501	Arm 3 = ONLY active arm Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03418961
Oncology	Oncology, Breast	Breast-focused	SWOG S1703	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03723928
Oncology	Oncology, Gastrointestinal	GI, Colorectal	Alliance A022101	3D/IMRT/Protons Credentialing Req'd A Prospective Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR).	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05673148
Oncology	Oncology, Gastrointestinal	GI, Colorectal	CCTG-CO32	RT Provider linked to site; IMRT; Lab Kit Shipmt Form The NEO-RT Trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06205485
Oncology	Oncology, Gastrointestinal	GI, Colorectal	NRG-GI008	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05174169
Oncology	Oncology, Gastrointestinal	GI, Colorectal	WAKE FOREST WF-1806	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03998202
Oncology	Oncology, Gastrointestinal	GI, Esophageal/Gastric	ALLIANCE A022102	A Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma.	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05677490

Oncology	Oncology, Gastrointestinal	GI, Esophageal/Gastric	ECOG-ACRIN EA2234	Req'd: EA2234 Site Registration Form A Randomized Phase III/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07001748
Oncology	Oncology, Gastrointestinal	GI, Esophageal/Gastric	NRG-GI006	Req'd: IMRT, IMPT-PBS Credentialing-Ability to do PROTON Radiation at site Phase III Randomized Trial of Proton Beam Therapy (PBT) versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03801876
Oncology	Oncology, Gastrointestinal	GI, Misc	NRG-CC005	FORTE: A study to determine whether a colonoscopy should be done every 5 years or every 10 years in people with 1 or 2 small growths (polyps) removed from their colon	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05080673
Oncology	Oncology, Gastrointestinal	GI, Pancreatic	ECOG-ACRIN EA2192	Site Specific DTL Req'd APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04858334
Oncology	Oncology, Gastrointestinal	GI, Pancreatic	NRG-GI011	Pre-Registration: IMRT Credentialing A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06958328
Oncology	Oncology, Gastrointestinal	GI, Pancreatic	SWOG S2104	Site Specific DTL Req'd Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05040360
Oncology	Oncology, Gastrointestinal	GI, Small Bowel	SWOG S1922	Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04205968
Oncology	Oncology, Genitourinary	GU, Bladder/Urothelia	Alliance A032103	Site DTL Req'd MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial CaNcer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05987241
Oncology	Oncology, Genitourinary	GU, Bladder/Urothelial	ECOG-ACRIN EA8192	Site DTL Req'd A Phase III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04628767
Oncology	Oncology, Genitourinary	GU, Bladder/Urothelial	NRG-GU014	Radiation credentialing (see protocol), Site DTL Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation And Concurrent Chemotherapy For High-Grade T1 Bladder Cancer (PARRC Trial)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06770582
Oncology	Oncology, Genitourinary	GU, Bladder/Urothelial	NRG-GU015	Req'd: IMRT & IGRT Credentialing The Phase III Adaptive Radiation And Chemotherapy For Muscle Invasive Bladder Cancer Trial (ARCHER)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07097142
Oncology	Oncology, Genitourinary	GU, Bladder/Urothelial	SWOG S2427	Req'd: Site DTL Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07061964
Oncology	Oncology, Genitourinary	GU, Misc	Alliance A031702	Site DTL Req'd Phase II Study Of Cabozantinib In Combination With Nivolumab And Ipilimumab In Rare Genitourinary Tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03866382
Oncology	Oncology, Genitourinary	GU, Misc	Alliance A092204	Site DTL Req'd A Phase 3 Study of Cabozantinib in Combination with Cemiplimab (Regn2810) (Cabo-Cemiplimab (Regn2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer.	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06900595
Oncology	Oncology, Genitourinary	GU, Misc	AGCT1531	Pediatric enrollments allowed at Mercy STL Pediatric Clinic ONLY A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03067181
Oncology	Oncology, Genitourinary	GU, Misc	AGCT1532	Pediatric enrollments allowed at Mercy STL Pediatric Clinic ONLY Req's Study Chair App for NCTN Site Participation A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Oncology, Genitourinary	GU, Prostate	CCTG-PR24	Req'd: IMRT-ICRT, HRD, LDR Credentialing Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment: A Non-Inferiority, Phase III Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost in Patients with Unfavorable Risk Localized Prostate Cancer (ASCENDE-SBRT)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06235697
Oncology	Oncology, Genitourinary	GU, Prostate	ECOG-ACRIN EA8191	PECT Body Quantitative & SNMMI Axumin Image Training Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence.	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04423211
Oncology	Oncology, Genitourinary	GU, Prostate	NRG-GU008	Pre-Registration: Study Agent Shipment Form & IMRT Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04134260
Oncology	Oncology, Genitourinary	GU, Prostate	NRG-GU013	Req'd IMRT & Proton Beam credentialing The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05946213
Oncology	Oncology, Genitourinary	GU, Prostate	SWOG S1802	Site credentialing required Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03678025
Oncology	Oncology, Genitourinary	GU, Prostate	SWOG S2312	A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06470243
Oncology	Oncology, Genitourinary	GU, Prostate	URCC-22053	Req'd: Coordinator Training, DXA Machine Cert & DXA Tech Cert High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05838716
Oncology	Oncology, Genitourinary	GU, Prostate	Alliance A032302	Req'd: Site DTL Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE).	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06931340
Oncology	Oncology, Genitourinary	GU, Prostate	Alliance A032304	Req'd: Site DTL Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07200830
Oncology	Oncology, Genitourinary	GU, Renal Cell	Alliance A032201	Req'd: Site DTL Short Term Intensified Pembrolizumab (KEYtruda) and Tivozanib for High-risk renal cell carcinoma – STRIKE	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06661720
Oncology	Oncology, Genitourinary	GU, Renal Cell	NRG-GU012	Req'd: IMRT & IGRT Credentialing Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05327686

Oncology	Oncology, Genitourinary	GU, Renal Cell	SWOG S1931	Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04510597
Oncology	Oncology, Gynecologic	GYN, Cervical	NRG-GY037	Req'd: IMRT/IGRT Credentialing; Site DTL A Phase III study of induction pembrolizumab and chemotherapy followed by chemoradiation and pembrolizumab versus chemoradiation and pembrolizumab both followed by pembrolizumab for high risk locally advanced cervical cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07061977
Oncology	Oncology, Gynecologic	GYN, Germ Cell & Misc	AGCT1531	Pediatric enrollments allowed at Mercy STL Pediatric Clinic ONLY A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03067181
Oncology	Oncology, Gynecologic	GYN, Germ Cell & Misc	AGCT1532	Pediatric enrollments allowed at Mercy STL Pediatric Clinic ONLY Req's Study Chair App for NCTM Site Participation A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Oncology, Gynecologic	GYN, Ovarian	NRG-CC008	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04251052
Oncology	Oncology, Gynecologic	GYN, Ovarian	NRG-GY036	A Phase II Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06580314
Oncology	Oncology, Gynecologic	GYN, Ovarian	ECOG-ACRIN EAY191-N4	Req's Site DTL A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancer: ComboMATCH Treatment Trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05564377
Oncology	Oncology, Gynecologic	GYN, Uterine (Endometrial)	NRG-CC010	CC010 Surgeon Credentialing A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05646316
Oncology	Oncology, Gynecologic	GYN, Uterine (Endometrial)	NRG-GY026	Site DTL Req'd A Phase III/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab/trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05262225
Oncology	Oncology, Gynecologic	GYN, Uterine (Endometrial)	NRG-GY032	Req: Pathologist attestation form & CCG RRA Designation Form A Phase II Study Of Tailored Adjuvant Therapy In Pole-Mutated And P53-Wildtype/NSMP Early-Stage Endometrial Cancer (Rainbo Blue & Taper)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05640989
Oncology	Oncology, Gynecologic	GYN, Uterine (Endometrial)	NRG-GY035	A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07198074
Oncology	Oncology, Gynecologic	GYN, Vulvar	NRG-GY024	IMRT Credentialing, DTL & Investigator Skill Verification Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III), a prospective phase II treatment trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05076942
Oncology	Oncology, Head & Neck	H&N, Melanoma	SWOG S2101	Site Specific DTL Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05136196
Oncology	Oncology, Head & Neck	H&N, Supportive Care	Alliance A222301	Pre-Reg Require: Site DTL High-dose Prophylactic Gabapentin (HOPE) to Prevent Opioid use for Oral Mucositis Pain during Head and Neck Chemoradiotherapy: A Phase III Clinical trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06992427
Oncology	Oncology, Head & Neck	H&N, Supportive Care	NRG-CC013	Pre-Reg Requirements: Study Agent Shipment form, Radiation Credentialing & Site DTL A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06532279
Oncology	Oncology, Head & Neck	Head & Neck	Alliance A092105	Req'd: Site DTL Randomized phase 2 study of nivolumab and ipilimumab with or without cabozantinib in patients with advanced nasopharyngeal carcinoma that have progressed after platinum treatment and immunotherapy	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05904080
Oncology	Oncology, Head & Neck	Head & Neck	Alliance A092205	Pre-Reg Reqmts: Site DTL Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06589804
Oncology	Oncology, Head & Neck	Head & Neck	ECOG-ACRIN EA3132	IMRT Credentialing Req'd, section 5.2.3 Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT02734537
Oncology	Oncology, Head & Neck	Head & Neck	ECOG-ACRIN EA3191	Site DTL, IMRT Credentialing (Proton credentialing req'd if using) A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04671667
Oncology	Oncology, Head & Neck	Head & Neck	ECOG-ACRIN EA3231	A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600E	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06475989
Oncology	Oncology, Head & Neck	Head & Neck	NRG-HN006	ePRO online train., IGRT & IMRT credentialing, HN006 surgeon training/credentialing Randomized Phase III/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04333537
Oncology	Oncology, Head & Neck	Head & Neck	NRG-HN010	Site Specific DTL, Study Agent Shipment Form A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtrastine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05408845
Oncology	Oncology, Head & Neck	Head & Neck	NRG-HN011	Site DTL Req'd A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06029270
Oncology	Oncology, Head & Neck	Head & Neck	NRG-HN014	Pre-Reg: IRT Credentialing & Proton cred if appropriate, Protocol Training, Surgeon training & Site DTL Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06568172
Oncology	Oncology, Head & Neck	Head & Neck	RTOG 1216	Pre-Registration: IMRT Credentialing Randomized Phase III/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Oncology, Lung	Lung	Alliance A081801	PATIENTS ENROLL DIRECTLY TO A081801 NOW Site Specific DTL Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04267848
Oncology	Oncology, Lung	Lung	Alliance CTIU2317-A082304-S2402	Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06632327

Oncology	Oncology, Lung	Lung	ECOG-ACRIN EA5162	Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03191149
Oncology	Oncology, Lung	Lung	ECOG-ACRIN EA5182	Req'd: Site DTL Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04181060
Oncology	Oncology, Lung	Lung	ECOG-ACRIN EA5221	Site DTL Req'd A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06096844
Oncology	Oncology, Lung	Lung	NRG-LU008	Radiation Credentialing-IGRT, IMRT & Protons (if used) Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05624996
Oncology	Oncology, Lung	Lung	SWOG LungMAP	**Protocol Specific Training Req'd for ALL LungMap** A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT03851445
Oncology	Oncology, Lung	Lung	SWOG S1800E	Req'd: Site DTL, CLASS S1800E Site Init Train A Randomized Phase III/III Study of Docetaxel and Ramucicromab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06616584
Oncology	Oncology, Lung	Lung	SWOG S1900G	Site DTL Required A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucicromab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05642572
Oncology	Oncology, Lung	Lung	SWOG S1900J	Site DTL Required A Phase II Study of Amivantamab SC (Subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06116682
Oncology	Oncology, Lung	Lung	SWOG S1900K	Site DTL Required A Randomized Phase II Study of Tepotinib with or Without Ramucicromab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06031688
Oncology	Oncology, Lung	Lung	SWOG S2414	Site DTL Required A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non-Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06498635
Oncology	Oncology, Lung	Lung, Small Cell	NRG-CC009	Pre-Reg: Neurocog, IMRT & SRS Cred & Hippo, Phy Cred Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04804644
Oncology	Oncology, Lung	Lung, Small Cell	NRG-LU007	3D, IMRT & IGRT Credentialing & Site DTL Req'd A Randomized Phase III/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04402788
Oncology	Oncology, Lung	Lung, Small Cell	SWOG S1827	IMRT Certification & RT Provider linked to site A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04155034
Oncology	Oncology, Lung	Lung, Small Cell	SWOG S2409	Req'd: Site DTL PRISM: Precision in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab with or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06769126
Oncology	Oncology, Lymphoma	Lymphoma	Alliance A052101	Req'd: Site DTL A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05976763
Oncology	Oncology, Lymphoma	Lymphoma	ECOG-ACRIN EAQ211	Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT06002828
Oncology	Oncology, Lymphoma	Lymphoma	SWOG S1925	Site DTL Req'd Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04269902
Oncology	Oncology, Lymphoma	Lymphoma	SWOG S2005	Req'd: Site DTL A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04840602
Oncology	Oncology, Melanoma	Melanoma	ECOG-ACRIN EA6232	Req'd: Submission of Site Registration Form A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT07040280
Oncology	Oncology, Melanoma	Melanoma	SWOG S2101	Site Specific DTL Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers -- an immunMATCH Pilot Study	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05136196
Oncology	Oncology, Misc.	Biorepository, Early Detection	Alliance A151804	Establishment of a national biorepository to advance studies of immune-related adverse events	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04242095
Oncology	Oncology, Misc.	Biorepository, Early Detection	NCI PDM9846	Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT02474160
Oncology	Oncology, Misc.	Early Detection	Alliance A212102	Blinded Reference Set for Multicancer Early Detection Blood Tests	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05334069
Oncology	Oncology, Misc.	Population Health	NCI DCP-001	Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	n/a
Oncology	Oncology, Misc. Treatment Trials		Alliance A021901	Req's: Site DTL & Lutathera On Boarding Form Randomized phase II trial of lutetium Lu 177 dotatate versus everolimus in somatostatin receptor positive bronchial neuroendocrine tumors	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT04665739
Oncology	Oncology, Misc. Treatment Trials		ECOG-ACRIN EAY191	Req'd: Site DTL Molecular Analysis for Combination Therapy Choice (ComboMATCH) SEE LIST OF TREATMENT SUB-STUDIES ON JIT PAGE	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05564377
Oncology	Oncology, Misc. Treatment Trials		ECOG-ACRIN EAY191-N4	Req's Site DTL A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancer: ComboMATCH Treatment Trial	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05554328

Oncology	Oncology, Misc. Treatment Trials		SWOG S2012	Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)	St. Louis, St. Louis-South, Springfield, Joplin, Fort Smith, Oklahoma City	NCT05058651
----------	----------------------------------	--	------------	---	--	---